Regeneron Hopes Its High-Dose Aflibercept Will Ease Eylea Pressure
Execs Expect BCMA Bispecific To Stand Out In Competitive Space
Eylea sales were below consensus for the second quarter in a row, but aflibercept 8mg approval in late June could offset the decline. Also, a late 2023 filing is planned for linvoseltamab in myeloma.
